What Randomized Trials Say About Medical Marijuana for Psychiatric and Neurologic Conditions | Research

The takeaway

Reviewing only randomized trials of plant-based cannabis (not synthetics), the evidence is limited across psychiatric and neurologic conditions, with clinicians urged to use evidence-based approaches even for Schedule I substances.

Read this if you are considering medical marijuana for a psychiatric or neurologic condition and want to know what randomized trial evidence actually exists.

RCT evidence for phytocannabinoids remains limited across all psychiatric and neurologic conditions

What the researchers found

This review took a deliberately narrow approach, examining only randomized clinical trials of phytocannabinoids (plant-derived cannabis) for psychiatric and neurologic conditions, excluding synthetic products like dronabinol and nabilone.

The search identified trials in dementia, multiple sclerosis, Parkinson's disease, Huntington's disease, schizophrenia, social anxiety disorder, depression, tobacco use disorder, and neuropathic pain.

The overall evidence base was thin. While some conditions showed promising signals, none had sufficient evidence for strong clinical recommendations. The variability between state medical marijuana laws in which conditions are approved for treatment further complicated the picture.

The authors emphasized that even for substances federally classified as illegal, clinicians must maintain evidence-based approaches and ensure patients have tried treatments with stronger evidence before turning to medical marijuana.

Why it matters

This review highlights a critical gap: state medical marijuana laws approve cannabis for conditions where RCT evidence of phytocannabinoid efficacy may be weak or absent. This disconnect between policy and evidence creates challenges for clinicians.

The numbers in context

Conditions with identified RCTs: dementia, MS, Parkinson's, Huntington's, schizophrenia, social anxiety, depression, tobacco use disorder, neuropathic pain. State medical marijuana laws cover highly variable condition lists.

How the study worked

PubMed search for randomized clinical trials of phytocannabinoids in human subjects for psychiatric and neurologic disorders. Excluded commercially available synthetics (dronabinol, nabilone, nabiximols) and synthetic cannabinoids.

What this study cannot tell us

Excluding synthetic cannabinoids and nabiximols removes a substantial portion of the evidence base. RCTs of plant cannabis are rare partly because of regulatory barriers, so the lack of evidence does not necessarily mean lack of efficacy. The review predates several important CBD trials.

How to read the evidence

Systematic review limited to RCTs. Moderate because the methodology is appropriate but the underlying evidence base is thin.

When this study was published

Published in 2017.

The bigger picture

The review underscores a recurring tension in cannabis medicine: patients and legislators are moving faster than the evidence base. By focusing specifically on plant-based cannabis RCTs (the form most patients actually use), the review reveals how little gold-standard evidence supports the conditions for which millions of patients obtain medical marijuana.

Questions still open

Should state medical marijuana condition lists be based on RCT evidence? Would regulatory reform enabling more phytocannabinoid RCTs close the evidence gap? How should clinicians advise patients in conditions where medical marijuana is legal but evidence is limited?

Common questions

Is there good evidence for medical marijuana in mental health conditions?

This review found limited RCT evidence of plant-based cannabis for any psychiatric condition. While some trials showed promise in social anxiety, neuropathic pain, and other conditions, the evidence was insufficient for strong clinical recommendations.

Why is the evidence so limited?

Cannabis's Schedule I federal classification creates major barriers to conducting rigorous clinical trials. This has resulted in a situation where medical marijuana is legally available in many states for conditions where high-quality evidence is lacking.

Read the original research

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

The mental health clinician, 7(1), 29-38

View on PubMed ↗Publisher’s paper ↗

Citation

Noel, Christopher. (2017). Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.. The mental health clinician, 7(1), 29-38. https://doi.org/10.9740/mhc.2017.01.029